Prize Fund for HIV/AIDS Act - Revision history

Ed at 21:26, 14 March 2017

2017-03-14T21:26:42Z

Julia at 19:08, 2 September 2016

2016-09-02T19:08:06Z

Julia at 18:19, 2 September 2016

2016-09-02T18:19:19Z

Julia at 21:41, 31 August 2016

2016-08-31T21:41:08Z

MarcelaInteriano at 16:09, 10 June 2016

2016-06-10T16:09:42Z

RichardGoldman: Created page with "The Prize Fund for HIV/AIDS Act is a [http://www.edegan.com/wiki/index.php/Patent_Reform#Legislation_Considered_in_Previous_Congressional_Sessions patent reform act] proposed..."

2016-06-01T21:26:31Z

Created page with "The Prize Fund for HIV/AIDS Act is a [http://www.edegan.com/wiki/index.php/Patent_Reform#Legislation_Considered_in_Previous_Congressional_Sessions patent reform act] proposed..."

imported>Albert at 22:34, 19 February 2016

2016-02-19T22:34:39Z

imported>Albert: /* Provisions */

2016-02-19T22:25:16Z

Provisions

imported>Albert: /* Heterogeneity of Patent and Prize Systems */

2016-02-19T21:56:54Z

Heterogeneity of Patent and Prize Systems

imported>Albert at 21:56, 19 February 2016

2016-02-19T21:56:30Z

← Older revision		Revision as of 21:26, 14 March 2017
Line 2:		Line 2:

	The [[Prize System for Inventions\|Prize Fund]] for HIV/AIDS Act is a patent reform act proposed in a previous congressional session.		The [[Prize System for Inventions\|Prize Fund]] for HIV/AIDS Act is a patent reform act proposed in a previous congressional session.
		+	See: https://www.congress.gov/bill/112th-congress/senate-bill/1138

	==Summary==		==Summary==

@@ Line 41: / Line 41: @@
 The act nullifies patents on manufacturing processes of drugs, so that no company may hold the patent on the manufacturing process of a drug. However, a company becomes eligible for prize funds by holding a patent on the manufacturing process they use to create a drug. [Bill language: ''...in the case of a manufacturing process for a qualifying treatment for HIV/AIDS, the holder of the patent with respect to such process...'']. No new firms may be eligible for prize funds if they use a manufacturing process they did not hold a patent for.
-[[Category: Internal]]
+[[Category: Public]]
-[[Internal Classification::Legislation| ]]
+[[Public Classification::Legislation| ]]

← Older revision		Revision as of 18:19, 2 September 2016
Line 1:		Line 1:
−	~~[[Category: Internal]]~~
−	~~[[Internal Classification::Legislation]]~~
−
	Return to [[Innovation Policy#Patent Reform \| Patent Reform]].		Return to [[Innovation Policy#Patent Reform \| Patent Reform]].

Line 43:		Line 40:

	The act nullifies patents on manufacturing processes of drugs, so that no company may hold the patent on the manufacturing process of a drug. However, a company becomes eligible for prize funds by holding a patent on the manufacturing process they use to create a drug. [Bill language: ''...in the case of a manufacturing process for a qualifying treatment for HIV/AIDS, the holder of the patent with respect to such process...'']. No new firms may be eligible for prize funds if they use a manufacturing process they did not hold a patent for.		The act nullifies patents on manufacturing processes of drugs, so that no company may hold the patent on the manufacturing process of a drug. However, a company becomes eligible for prize funds by holding a patent on the manufacturing process they use to create a drug. [Bill language: ''...in the case of a manufacturing process for a qualifying treatment for HIV/AIDS, the holder of the patent with respect to such process...'']. No new firms may be eligible for prize funds if they use a manufacturing process they did not hold a patent for.
		+
		+	[[Category: Internal]]
		+	[[Internal Classification::Legislation\| ]]

← Older revision		Revision as of 21:41, 31 August 2016
Line 1:		Line 1:
		+	[[Category: Internal]]
		+	[[Internal Classification::Legislation]]
		+
	Return to [[Innovation Policy#Patent Reform \| Patent Reform]].		Return to [[Innovation Policy#Patent Reform \| Patent Reform]].

← Older revision		Revision as of 16:09, 10 June 2016
Line 1:		Line 1:
−	The Prize Fund for HIV/AIDS Act is a ~~[http://www.edegan.com/wiki/index.php/Patent_Reform#Legislation_Considered_in_Previous_Congressional_Sessions~~ patent reform act] proposed in a previous congressional session.	+	Return to [[Innovation Policy#Patent Reform \| Patent Reform]].
		+
		+	The [[Prize System for Inventions\|Prize Fund]] for HIV/AIDS Act is a patent reform act proposed in a previous congressional session.

	==Summary==		==Summary==

← Older revision	Revision as of 21:26, 1 June 2016
(No difference)

@@ Line 1: / Line 1: @@
 ==Summary==
 S. 1138[https://www.govtrack.us/congress/bills/112/s1138/text], Prize Fund for HIV/AIDS Act, was proposed by Sen. Bernie Sanders during the 112th session of Congress. The bill sought to change the current patent system for drugs treating AIDS to a prize system where the inventor would receive a lump sum payment for discovering a drug, and then void any claim on a paten for the drug. The bill died in Congress, and was re-introduced as S. 626 in the 113th Congressional session[https://www.govtrack.us/congress/bills/113/s626].
 ==Provisions==

@@ Line 16: / Line 16: @@
 *Prize Fund operates as a revolving fund.
-*Secretary of Treasury credits Fund with proceeds.
+**Secretary of Treasury credits Fund with proceeds.
 *Prize Fund Director responsible for giving prizes for medical innovation drugs.
 ==Heterogeneity of Patent and Prize Systems==
 The act nullifies patents on manufacturing processes of drugs, so that no company may hold the patent on the manufacturing process of a drug. However, a company becomes eligible for prize funds by holding a patent on the manufacturing process they use to create a drug. [Bill language: ''...in the case of a manufacturing process for a qualifying treatment for HIV/AIDS, the holder of the patent with respect to such process...'']. No new firms may be eligible for prize funds if they use a manufacturing process they did not hold a patent for.

← Older revision		Revision as of 21:56, 19 February 2016
Line 21:		Line 21:
	==Heterogeneity of Patent and Prize Systems==		==Heterogeneity of Patent and Prize Systems==

−	The act nullifies patents on manufacturing processes of drugs, so that no company may hold the patent on the manufacturing process of a drug. However, a company becomes eligible for prize funds by holding a patent on the manufacturing process they use to create a drug. [Bill language: in the case of a manufacturing process for a qualifying treatment for HIV/AIDS, the holder of the patent with respect to such process]. No new firms may be eligible for prize funds if they use a manufacturing process they did not hold a patent for.	+	The act nullifies patents on manufacturing processes of drugs, so that no company may hold the patent on the manufacturing process of a drug. However, a company becomes eligible for prize funds by holding a patent on the manufacturing process they use to create a drug. [Bill language: ''...in the case of a manufacturing process for a qualifying treatment for HIV/AIDS, the holder of the patent with respect to such process...'']. No new firms may be eligible for prize funds if they use a manufacturing process they did not hold a patent for.